4DMedical Limited (ASX: 4DX) has become one of the most talked-about names on the ASX. Its shares have surged approximately 8% in a single session, changing hands at around A$6.00 per share at the time of writing, bringing the year-to-date gain to 32% and the 12-month return to an extraordinary 2,208%.
Figure 1: 4DMedical Limited logo representing the ASX-listed healthcare technology company [Courtesy: Monash University]
The rally has been fuelled by genuine commercial progress, including landmark regulatory approvals and contracts with some of the most respected healthcare institutions in the United States. But as 4DX shares continue to climb, a reasonable question is emerging — are investors chasing a story that has already been more than priced in?
4DMedical’s Lung Imaging Technology Is Driving Investor Interest
4DMedical is an ASX healthcare technology Company focused on lung imaging. Its flagship product, CT:VQ, is a software platform that enables healthcare providers to analyse airflow through the lungs in four dimensions, helping clinicians identify and treat respiratory diseases ranging from asthma to lung cancer.
Figure 2: CT:VQ lung imaging comparison showing traditional structure imaging versus non-contrast functional analysis [Courtesy: PR Newswire]
Regulatory Approval Marked a Turning Point for 4DX Shares
The Company’s 4DMedical share price trajectory changed decisively in 2025 when CT: VQ received regulatory approvals, clearing the path for commercial deployment across healthcare systems.
That approval triggered a rapid shift in how the market perceived 4DMedical, from a research and development Company carrying speculative risk, to a globally commercial business with real contracted revenue.
Tier-One US Partnerships Strengthen Market Confidence
The clinical partnerships 4DMedical has secured in the United States are not minor. The Company has signed contracts with Stanford University, the University of Miami, the Cleveland Clinic, and UC San Diego Health.
These are institutions with global reputations, and their adoption of CT:VQ has given the 4DX ASX healthcare technology story meaningful credibility with investors.
The Financial Reality Behind the Share Price Rally
While the commercial momentum is real, the financial picture requires careful reading. The Appendix 4D for the half-year ended 31 Dec 2025 shows revenue from ordinary activities of A$2.852 million, down 1% on the previous corresponding period.
Half-Year Results Highlight the Gap Between Revenue and Valuation
The half-year results for the period ended 31 Dec 2025 include:
- Revenue from ordinary activities of A$2.852 million, down 1% on the prior corresponding period
- Other income of A$2.699 million, down 44% on the prior corresponding period
- Adjusted net loss of A$16.195 million for the half-year ended 31 Dec 2025, an improvement of 18% on the prior period
- Statutory net loss attributable to members of A$153.863 million for the half-year ended 31 Dec 2025, up 1,124% on the prior period
- Net tangible assets per ordinary security of A$0.08 as at 31 Dec 2025, compared with A$(0.04) in the prior period
The Company does not pay any dividends to shareholders. 4DMedical remains firmly in a loss-making, growth and commercialisation phase, and the gap between its current revenue base and its market capitalisation is substantial.
Speculative Momentum Is Building in 4DX Shares
The 4DMedical share price has risen to levels that reflect significant investor optimism about the future. That optimism may prove well-founded, the product is real, the partnerships are credible, and the addressable market for lung imaging technolog is large.
However, companies at this stage of development often attract momentum-driven and speculative trading. Price increases can feed further price increases as investor sentiment amplifies the move. The risk is that if contract growth, revenue scaling, or clinical outcomes disappoint against elevated expectations, the share price can correct just as sharply as it advanced.
4DX shares are currently trading at a market capitalisation of A$3.50 billion against a revenue base of A$2.852 million for the half-year ended 31 Dec 2025. That is a valuation multiple that prices in a very long runway of successful execution.
4DMedical Share Price
4DMedical Limited (ASX: 4DX) is currently trading at A$5.630 per share, with a market capitalisation of A$3.50 billion. The 52-week range stands at A$0.225 to A$7.550 per share.
Figure 3: 4DMedical Limited (ASX: 4DX) share price performance over the past year [Courtesy: ASX]
Industry Outlook
The global lung imaging and respiratory diagnostics market is growing steadily, driven by rising rates of chronic respiratory disease, ageing populations across developed economies, and increasing adoption of AI-assisted diagnostic tools in clinical settings.
Healthcare technology Companies that can demonstrate measurable clinical outcomes and scalable software deployment are attracting institutional capital at an accelerating pace. 4DMedical’s positioning within this sector, if commercialisation executes as planned, addresses a genuine and expanding clinical need.
Future Direction and Impact on 4DX Investors
For investors already holding 4DX shares, the central consideration is execution risk versus valuation. The Company has done the hard work of securing regulatory approval and signing contracts with leading institutions.
The next phase, converting those partnerships into a growing, recurring revenue stream, is where the real test begins. For investors considering entry at current levels, the 4DMedical share price already reflects a great deal of the upside scenario.
The adjusted net loss of A$16.195 million for the half-year ended 31 Dec 2025 shows the Company is managing its cash burn more efficiently than before, which is a positive sign. But the distance between current revenue and the valuation embedded in 4DX ASX healthcare technology pricing today means there is limited room for disappointment.
The rally may well continue if commercial milestones are met. But chasing 4DX shares at these levels, without accepting that the risk-reward has shifted materially from where it stood 12 months ago, is a position that warrants careful thought.
ALSO READ:Auric Mining Names Processing Lead to Drive Burbanks Mill Development
Frequently Asked Questions
Q1. What does 4DMedical do?
Ans. 4DMedical develops lung imaging software that allows healthcare providers to analyse airflow through the lungs.
Q2. Why have 4DX shares risen so sharply?
Ans. The 4DMedical share price surged after CT:VQ received regulatory approvals in 2025 and the Company signed contracts with major US healthcare institutions including Stanford University and Cleveland Clinic.
Q3. Is 4DMedical a profitable Company?
Ans. No. 4DMedical reported an adjusted net loss of A$16.195 million for the half-year ended 31 Dec 2025.
Q4. What was 4DMedical’s revenue for the half-year ended 31 Dec 2025?
Ans. Revenue from ordinary activities was A$2.852 million for the half-year ended 31 Dec 2025, down 1% on the prior corresponding period.
Q5. What is the risk of investing in 4DX shares at current levels?
Ans. The 4DX ASX healthcare technology valuation of A$3.50 billion prices in substantial future growth.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on publicly available information, and reporting published on 2 Apr 2026. Share price and market capitalisation data reflect figures provided at the time of publication. Investing in securities involves risk, including the risk of losing your invested capital. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies or organisations mentioned.
Sources
https://www.asx.com.au/markets/company/4DX
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-03062375-3A688309
Last modified: April 2, 2026
